US EditionPfizer's Decision Not to Pursue Phase 3 Trial of Weight-Loss Drug Raises Concerns
Summary by Clayton County Register
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Pfizer's Decision Not to Pursue Phase 3 Trial of Weight-Loss Drug Raises Concerns
Pfizer Inc.’s recent announcement that it will not proceed with a Phase 3 trial of a twice-daily formulation of a weight-loss drug has sent shockwaves through the pharmaceutical industry. The company’s stock experienced a significant drop of 4% in premarket trading on Friday following the news. The decision came after patients in an earlier study reported a high number of side effects related to the drug. Pfizer’s Phase 2b study of its oral GLP-…
·Elkader, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
